智通财经4月24日讯（记者 王俊仙 何凡）乙肝临床治愈新药的临床研发取得实质性进展，令广生堂 (300436.SZ)的市场关注度持续升温。今日晚间，广生堂披露全球首个三联全口服治疗方案获批开展II期 临床，而由于该II期临床试验被纳入优化创新药临床试验审评审批试点项目，业内预计项目后续临床进 度有望加速。 "能被纳入试点的项目在创新药、临床数据和药物作用机制等方面的要求较高，一旦被纳入将提升审评 审批效率，缩短审评周期，有助于助推联合方案尽早上市。"资深医药行业专家郭新峰告诉智通财经记 者，GST-HG131和GST-HG141两者分别针对抗乙肝病毒不同新靶点，在作用机制上预计存在协同互 补，而且该三联方案是全口服，有助于提升患者依从性，若最终能成功上市有望填补抗乙肝病毒类临床 治愈创新药的空白。 据智通财经记者了解，这是全球首个由两个完成II期临床入组的潜在First-in-class创新药组成的全口服方 案。 此前，广生堂曾因乙肝单药的临床数据而连续大涨，市场亦期待广生堂这家老牌乙肝治疗企业能依靠这 些创新疗法"焕发第二春"，实现从传统药企向乙肝创新领域的"关键一跃"。 三联方案临床验证有望加速推进 今年 ...

Summary of Conference Call on Guangsheng Pharmaceutical Company Overview - Guangsheng Pharmaceutical is a biopharmaceutical company listed on the Shenzhen Stock Exchange's ChiNext board, focusing on antiviral and liver health drug development since its establishment in 2015 [2][3]. Key Developments - The company has made significant progress in its clinical trials, particularly in the antiviral field, with the approval of its COVID-19 drug, Taizhongding, which has the lightest dosage and best antiviral effect among eight drugs in the market [3][4]. - The company is also advancing its hepatitis B treatment pipeline, specifically the drug 141 Nairu Kewei, which has completed a summary report for its Phase II clinical trial [3][4]. Clinical Trials and Innovations - The company is focusing on a unique treatment plan called the "Dengfeng Plan," which aims for clinical cure in hepatitis B patients. This plan includes a combination of existing nucleoside analogs and new drugs targeting hepatitis B core proteins [7][8]. - The drug 131, a small molecule inhibitor targeting surface antigens, is currently in Phase II trials and has shown promising results in reducing surface antigen levels in patients [9][10]. Regulatory Support - Guangsheng Pharmaceutical has received recognition from the National Medical Products Administration (NMPA) for its innovative drug review and approval pilot program, which is expected to expedite the clinical trial process [5][16][17]. - The company is part of a select group of projects recognized for their innovation and clinical data superiority, indicating strong governmental support for its initiatives [17][18]. Market Position and Future Prospects - The company is positioned as a leader in the hepatitis B treatment market, with its drugs being the first in class globally. The combination of 141 and 131 is expected to enhance treatment efficacy and patient outcomes [20][22]. - There is a strong emphasis on the unmet clinical needs in the hepatitis B market, with the company aiming to address these through its innovative treatment strategies [26][27]. Financial Performance - The company reported an expected revenue of approximately 4.35 to 4.6 billion yuan for the year, with a significant increase in gross margins for its main products [41][42]. - Despite a projected loss of 1.25 to 1.63 billion yuan due to increased marketing and team development costs, the company remains optimistic about its growth trajectory [41][42]. Strategic Collaborations - Guangsheng Pharmaceutical collaborates with leading research companies and contract development and manufacturing organizations (CDMOs) to enhance its research capabilities and clinical trial execution [12][13]. - The company is exploring various financing channels to support its innovative drug development, including potential capital market opportunities [47][52]. Conclusion - Guangsheng Pharmaceutical is on a promising path with its innovative hepatitis B treatments and strong regulatory support. The company aims to leverage its unique drug development strategies to meet significant market needs and enhance patient outcomes in the antiviral space [54][56].

Summary of Conference Call Company and Industry - The conference call primarily discusses **特保生物 (TeBao Bio)**, a company in the **pharmaceutical industry**, focusing on **clinical cures for hepatitis B** and related treatments. Key Points and Arguments 1. **Financial Performance**: - The company reported a **net profit of 828 million yuan**, a **49% increase year-over-year**. The **deducted net profit** was **827 million yuan**, reflecting a **42.73% growth**. This performance is attributed to the increasing recognition of their product, **派格宾 (Pegbivac)**, in the market and improved management efficiency, leading to a reduction in overall expense ratios and enhanced profitability [2][3][21]. 2. **Product Development**: - The company is focusing on **immunology and metabolic diseases**, with ongoing research and development projects. Notably, **Pegbivac** has received clinical trial approvals for new indications, including **clinical cure for hepatitis B** and applications in treating **thrombocytopenia** [3][11][14]. 3. **Clinical Trials and Regulatory Approvals**: - The company submitted an **NDA (New Drug Application)** for **Pegbivac** in March 2024, which is currently under review. This submission is significant as it is the first global NDA for a clinical cure for hepatitis B [5][10][11]. 4. **Market Penetration and Treatment Efficacy**: - The penetration rate of antiviral treatments remains low, indicating a substantial market opportunity. The company believes that as scientific understanding and treatment options improve, the acceptance and demand for hepatitis B treatments will increase [20][21][24]. 5. **Collaborations and Partnerships**: - The company has established collaborations with various organizations, including **九天生物 (Nine Sky Bio)**, to enhance its product pipeline and leverage advanced technologies in gene therapy and immunotherapy [14][25]. 6. **Future Outlook**: - The management expressed confidence in becoming a leader in the field of clinical cures for hepatitis B and related diseases. They anticipate continued growth in R&D investments aligned with project needs and market demands [11][37]. Other Important but Possibly Overlooked Content 1. **Sales Strategy**: - There is a focus on expanding the sales team in anticipation of product approvals, although the current hiring pace is cautious due to pending regulatory approvals [36]. 2. **Research and Development Focus**: - The company emphasizes that R&D investments will be driven by the need to solve clinical problems rather than merely increasing the number of projects. This strategic approach aims to ensure that resources are allocated effectively to high-potential areas [37]. 3. **Patient Engagement and Market Dynamics**: - The management highlighted the importance of educating patients and healthcare providers about the benefits of achieving clinical cures for hepatitis B, which could drive demand and acceptance in the market [30][32]. 4. **Long-term Vision**: - The company aims to address the broader population of hepatitis B patients, including those in non-active phases, by enhancing treatment options and improving patient outcomes through innovative therapies [29][31]. This summary encapsulates the critical insights from the conference call, reflecting the company's strategic direction, financial health, and market opportunities within the pharmaceutical industry.

Core Viewpoint - The company is actively advancing its clinical research and product pipeline in the field of chronic hepatitis B treatment, particularly focusing on the approval and market penetration of its drug, Paigebin, and its combination therapies [2][3]. Group 1: Clinical Developments - The latest approval timeline for the clinical cure indication for chronic hepatitis B is expected to be submitted to the National Medical Products Administration in March 2024, currently under technical review [2]. - The establishment of clinical cure outpatient clinics is ongoing, which is anticipated to positively impact sales by enhancing treatment standardization and increasing patient awareness [2]. - The company is also progressing with the registration application for its growth hormone product, which was accepted in January 2024 and is currently under technical review [2]. Group 2: Research and Development Strategy - The company plans to increase R&D investment in line with clinical needs, focusing on immunology and metabolism, with an upward trend in overall R&D spending as more projects enter clinical research [2][3]. - The company has established collaborations for various products, including ongoing preclinical studies and Phase I clinical trials, indicating a robust pipeline in liver disease and gene therapy [2][3]. Group 3: Market Insights and Future Outlook - The penetration rate of long-acting interferon in chronic hepatitis B treatment remains low, but the company believes that new therapies and combination strategies will increase the patient population receiving antiviral treatment [3]. - The company anticipates that the market for long-acting interferon will expand as new drugs for hepatitis B are launched, supported by evidence showing interferon’s effectiveness in reducing liver cancer risk [3]. - The company is exploring various real-world research projects to optimize hepatitis B treatment strategies, aiming to broaden the definition and scope of clinical cure populations [3].

Core Viewpoint - The article highlights the urgent need for improved diagnosis and treatment of chronic hepatitis B in China, where the current diagnosis rate is only 22% and treatment rate is 15%, significantly lagging behind the World Health Organization's goals for 2030 [1][2][4]. Group 1: Current Situation of Hepatitis B in China - Chronic hepatitis B poses a serious health threat, with approximately 75 million carriers in China, accounting for about one-third of the global total of 260 million [1][3]. - The average incidence of hepatitis B in China is 71.77 per 100,000 people, with a higher infection rate of 8.92% in the western regions compared to 6.61% and 5.23% in eastern and central regions, respectively [2][3]. - The low diagnosis and treatment rates are major barriers to effective management, with estimates suggesting that less than 24% of patients are diagnosed and only about 14% are receiving treatment [3][4]. Group 2: Treatment and Management Strategies - Current antiviral treatments can effectively suppress virus replication, preventing disease progression, although a complete cure is not yet achievable [2][6]. - The Chinese healthcare system is moving towards a "treat all" strategy to increase treatment coverage and reduce mortality rates, aligning with WHO's goal to eliminate hepatitis B as a public health threat by 2030 [4][6]. - The availability and affordability of antiviral medications have improved significantly, with many drugs now covered by national health insurance [2][6]. Group 3: Clinical Research and Innovations - Recent clinical trials, such as the "珠峰" project, have shown promising results, with over 8,848 patients achieving clinical cure status through various treatment protocols [8][9]. - The use of pegylated interferon α has demonstrated a clinical cure rate of 33.8% after 48 weeks of treatment, indicating progress in achieving better treatment outcomes [8][9]. - Ongoing research projects, including the "绿洲" project, aim to reduce the incidence of liver cancer among hepatitis B patients, showcasing the commitment to improving patient outcomes [9][10].

Group 1 - A total of 220 stocks were investigated by institutions in the past week, with YHLO being the most researched stock [1] - YHLO had 123 institutions participating in the research, including 39 fund companies, 32 securities companies, and 15 insurance companies [2] - For 2024, YHLO reported a revenue of 1.992 billion yuan, a decrease of 2.99% year-on-year, and a net profit attributable to shareholders of 302 million yuan, down 15.03% [2] - YHLO's non-recurring net profit attributable to shareholders was 288 million yuan, an increase of 31.16% year-on-year [2] - YHLO expressed confidence in its growth potential, driven by the large-scale promotion of its iTLA MAX domestic production line and the commercialization of its fully automated biochemical analyzer [2] Group 2 - ZSL Pharma plans to strengthen its market presence through core products like Wuling Capsules and Bailin Tablets, targeting broader coverage in lower-tier cities and community health centers [3] - ZSL Pharma aims to enhance its OTC market presence and improve brand awareness through various promotional activities [3] - ZSL Pharma is focusing on internet marketing and strengthening its sales team to improve market expansion capabilities [3] Group 3 - Guangshengtang's clinical project for its hepatitis B treatment has been included in an innovative drug clinical trial optimization project, indicating recognition from drug regulatory authorities [3] - The inclusion in the trial optimization project is expected to accelerate the drug approval process, benefiting hepatitis B patients [4] - Guangshengtang's hepatitis B plan features unique innovations, including an all-oral regimen and potential suppression of cccDNA [4] Group 4 - The A-share market saw a strong rise, with the Shanghai Composite Index increasing by 1.39%, surpassing the 3400-point mark [4] - The average increase for stocks under institutional research was 1.32%, with Shenghong Technology experiencing the largest gain of nearly 38% [4] - Shenghong Technology's projected net profit for Q1 2025 is between 780 million and 980 million yuan, reflecting significant year-on-year and quarter-on-quarter growth [4] - Shenghong Technology attributes its performance to its strategy of embracing AI and collaborating with leading international clients [4] Group 5 - Xingtum Control, Chaohongji, Buke Co., and Litong Technology all saw stock price increases exceeding 15% in the past week [5] - Xingtum Control is focused on aerospace measurement and control management, indicating a clear demand in specialized fields [5] - The company also sees significant potential in aerospace digital simulation for future industry development [5]